Industry News

Regeneron reports $2.11 billion in year-end revenue

For the fourth quarter ending Dec. 31, 2013, Regeneron has reported $610 million in revenue, which represents a 47% increase over the prior year’s period, and brings the total year-end revenue to $2.11 billion for 2013, which is a 53% increase over total year-end revenue for 2012, according to a company press release.

This growth was primarily attributed to Eylea sales, which amounted to $402 million in the U.S. alone for the fourth quarter, a 46% increase over the same period last year, and $1.41 billion in U.S. sales for the full year, as compared to $838 million for the full year prior, according to the release.

Non-GAAP net income was $259 million for the fourth quarter of 2013, compared to $171 million in the fourth quarter of 2012. For the full year, non-GAAP net income was $935 million, compared to $530 million for the full year 2012.

Regeneron reported GAAP net income of $97 million, or $0.98 per basic share and $0.86 per diluted share, in the fourth quarter of 2013, compared to $470 million ($4.92 per basic share, $4.08 per diluted share) in the fourth quarter of 2012.

GAAP net income was $424 million, or $4.33 per basic share and $3.81 per diluted share, for the full year 2013, compared to $750 million ($7.92 per basic share, $6.75 per diluted share) for the full year 2012, the release said.

The decrease in both fourth quarter and full year 2013 GAAP net income resulted primarily from the non-cash tax benefit of $336 million recorded in the fourth quarter of 2012, the company's recognition of an income tax provision commencing in 2013 and higher operating expenses in 2013, according to the release.

For the fourth quarter ending Dec. 31, 2013, Regeneron has reported $610 million in revenue, which represents a 47% increase over the prior year’s period, and brings the total year-end revenue to $2.11 billion for 2013, which is a 53% increase over total year-end revenue for 2012, according to a company press release.

This growth was primarily attributed to Eylea sales, which amounted to $402 million in the U.S. alone for the fourth quarter, a 46% increase over the same period last year, and $1.41 billion in U.S. sales for the full year, as compared to $838 million for the full year prior, according to the release.

Non-GAAP net income was $259 million for the fourth quarter of 2013, compared to $171 million in the fourth quarter of 2012. For the full year, non-GAAP net income was $935 million, compared to $530 million for the full year 2012.

Regeneron reported GAAP net income of $97 million, or $0.98 per basic share and $0.86 per diluted share, in the fourth quarter of 2013, compared to $470 million ($4.92 per basic share, $4.08 per diluted share) in the fourth quarter of 2012.

GAAP net income was $424 million, or $4.33 per basic share and $3.81 per diluted share, for the full year 2013, compared to $750 million ($7.92 per basic share, $6.75 per diluted share) for the full year 2012, the release said.

The decrease in both fourth quarter and full year 2013 GAAP net income resulted primarily from the non-cash tax benefit of $336 million recorded in the fourth quarter of 2012, the company's recognition of an income tax provision commencing in 2013 and higher operating expenses in 2013, according to the release.